MedKoo Cat#: 413963 | Name: Dup-697
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DuP-697, also known as S-6907 and BFMT, is a cyclooxygenase 2 (COX-2) inhibitor potentially for the treatment of rheumatoid arthritis (RA) and osteoarthritis. DuP-697 alone exerted antiproliferative, antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. DuP-697 significantly suppressed K562 cells and primary CML cells growth and induced apoptosis in a concentration-dependent manner and the growth-inhibiting effect was independent on Philadelphia chromosome. DuP-697, at concentrations ranges which do not inhibit PGHS-1 activity, significantly attenuated the inhibition of PGHS-1 that was caused by aspirin and indomethacin.

Chemical Structure

Dup-697
Dup-697
CAS#88149-94-4

Theoretical Analysis

MedKoo Cat#: 413963

Name: Dup-697

CAS#: 88149-94-4

Chemical Formula: C17H12BrFO2S2

Exact Mass: 409.9446

Molecular Weight: 411.30

Elemental Analysis: C, 49.64; H, 2.94; Br, 19.43; F, 4.62; O, 7.78; S, 15.59

Price and Availability

Size Price Availability Quantity
10mg USD 500.00 2 Weeks
25mg USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Dup 697; Dup-697; Dup697; S-6907; S 6907; S6907; BFMT;
IUPAC/Chemical Name
Thiophene, 5-bromo-2-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-
InChi Key
AJFTZWGGHJXZOB-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H12BrFO2S2/c1-23(20,21)14-8-4-11(5-9-14)15-10-16(18)22-17(15)12-2-6-13(19)7-3-12/h2-10H,1H3
SMILES Code
O=S(C1=CC=C(C2=C(C3=CC=C(F)C=C3)SC(Br)=C2)C=C1)(C)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
is a member of the diaryl heterocycle group of selective COX-2 inhibitors which includes MK-966 (rofecoxib), SC-58125, and celecoxib. When tested on isolated recombinant enzymes, DuP-697 is at least 50 times more potent in the inhibition of COX-2 than COX-1. The IC50 values for human recombinant COX-2 are 80 and 40 nM at 5 and 10 minutes, respectively. The IC50 for the inhibition of human recombinant COX-1 after the same time intervals is 9 µM.3 DuP-697 also attenuates the COX-1 inhibitory activity of non-selective COX inhibitors such as indomethacin.

Preparing Stock Solutions

The following data is based on the product molecular weight 411.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Peng HL, Zhang GS, Liu JH, Gong FJ, Li RJ. Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation. Ann Hematol. 2008 Feb;87(2):121-9. doi: 10.1007/s00277-007-0385-4. Epub 2007 Nov 13. PMID: 17999062. 2: Altun A, Turgut NH, Kaya TT. Anticancer effect of COX-2 inhibitor DuP-697 alone and in combination with tyrosine kinase inhibitor (E7080) on colon cancer cell lines. Asian Pac J Cancer Prev. 2014;15(7):3113-21. doi: 10.7314/apjcp.2014.15.7.3113. PMID: 24815456. 3: Rosenstock M, Danon A, Rimon G. PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity. Biochim Biophys Acta. 1999 Aug 25;1440(1):127-37. doi: 10.1016/s1388-1981(99)00105-5. PMID: 10477832. 4: Churchman A, Baydoun AR, Hoffman R. Inhibition of angiogenic tubule formation and induction of apoptosis in human endothelial cells by the selective cyclooxygenase-2 inhibitor 5-bromo-2-(4-fluorophenyl)-3-(methylsulfonyl) thiophene (DuP-697). Eur J Pharmacol. 2007 Nov 14;573(1-3):176-83. doi: 10.1016/j.ejphar.2007.06.057. Epub 2007 Jul 7. PMID: 17643408. 5: Burdan F, Dudka J, Szumilo J, Korobowicz A, Klepacz L. Prenatal effects of DuP-697-the irreversible, highly selective cyclooxygenase-2 inhibitor. Reprod Toxicol. 2003 Jul-Aug;17(4):413-9. doi: 10.1016/s0890-6238(03)00045-5. PMID: 12849852. 6: Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, Smith C, Hewes WE, Ackerman NR. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther. 1990 Jul;254(1):180-7. PMID: 2366180. 7: Kaya TT, Altun A, Turgut NH, Ataseven H, Koyluoglu G. Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells. Asian Pac J Cancer Prev. 2016;17(3):1103-10. doi: 10.7314/apjcp.2016.17.3.1103. PMID: 27039732. 8: de Vries EF, van Waarde A, Buursma AR, Vaalburg W. Synthesis and in vivo evaluation of 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression. J Nucl Med. 2003 Oct;44(10):1700-6. PMID: 14530489. 9: Agarwal V, Hodgkinson VC, Eagle GL, Scaife L, Lind MJ, Cawkwell L. Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. Int J Oncol. 2013 Mar;42(3):1088-92. doi: 10.3892/ijo.2013.1784. Epub 2013 Jan 22. PMID: 23338544. 10: Joshi AS, Raghavan N, Williams RM, Takahashi K, Shingu H, King SY. Simultaneous quantification of an anti-inflammatory compound (DuP 697) and a potential metabolite (X6882) in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1994 Oct 3;660(1):143-50. doi: 10.1016/0378-4347(94)00272-x. PMID: 7858707.